KR101061328B1 - 피리딘[3,4-ｂ]피라지논 - Google Patents
피리딘[3,4-ｂ]피라지논 Download PDFInfo
- Publication number
- KR101061328B1 KR101061328B1 KR1020087028465A KR20087028465A KR101061328B1 KR 101061328 B1 KR101061328 B1 KR 101061328B1 KR 1020087028465 A KR1020087028465 A KR 1020087028465A KR 20087028465 A KR20087028465 A KR 20087028465A KR 101061328 B1 KR101061328 B1 KR 101061328B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- alkyl
- optionally substituted
- propoxyethyl
- pyrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1c(*)nc(*)c(*)c1* Chemical compound Cc1c(*)nc(*)c(*)c1* 0.000 description 3
- IRHNQVINMHHEIO-UHFFFAOYSA-N CC(C)(C)OC(Nc(cn1)ccc1Cl)=O Chemical compound CC(C)(C)OC(Nc(cn1)ccc1Cl)=O IRHNQVINMHHEIO-UHFFFAOYSA-N 0.000 description 1
- YCBOUHLCYYKTFG-UHFFFAOYSA-N CC(C)(C)OC(Nc(cnc(Cl)c1)c1I)=O Chemical compound CC(C)(C)OC(Nc(cnc(Cl)c1)c1I)=O YCBOUHLCYYKTFG-UHFFFAOYSA-N 0.000 description 1
- IVCUZGCZGTVUPU-UHFFFAOYSA-N CCCOCCN(c(cc(-c(cc1)ccc1OC(C)C)nc1)c1N=C1N2CCN(CCO)CC2)C1=O Chemical compound CCCOCCN(c(cc(-c(cc1)ccc1OC(C)C)nc1)c1N=C1N2CCN(CCO)CC2)C1=O IVCUZGCZGTVUPU-UHFFFAOYSA-N 0.000 description 1
- RALGFLBLQQDLCM-UHFFFAOYSA-N CCCOCCN(c(cc(-c(cc1C)ccc1OC)nc1)c1N=C1N2CCN(CCO)CC2)C1=O Chemical compound CCCOCCN(c(cc(-c(cc1C)ccc1OC)nc1)c1N=C1N2CCN(CCO)CC2)C1=O RALGFLBLQQDLCM-UHFFFAOYSA-N 0.000 description 1
- SVHKUKDOJOYIMM-UHFFFAOYSA-N CCCOCCN(c(cc(-c(cccc1)c1O)nc1)c1N=C1N2CCN(CCO)CC2)C1=O Chemical compound CCCOCCN(c(cc(-c(cccc1)c1O)nc1)c1N=C1N2CCN(CCO)CC2)C1=O SVHKUKDOJOYIMM-UHFFFAOYSA-N 0.000 description 1
- CYLNBQNJAOVCQH-INIZCTEOSA-N CCCOCCN(c(cc(-c(cn1)ccc1OC)nc1)c1N=C1N(CC2)C[C@H]2O)C1=O Chemical compound CCCOCCN(c(cc(-c(cn1)ccc1OC)nc1)c1N=C1N(CC2)C[C@H]2O)C1=O CYLNBQNJAOVCQH-INIZCTEOSA-N 0.000 description 1
- FHFJVFOTDIRAOD-UHFFFAOYSA-N CCCOCCN(c(cc(-c(cn1)ccc1OC)nc1)c1N=C1N2CCN(CCCO)CC2)C1=O Chemical compound CCCOCCN(c(cc(-c(cn1)ccc1OC)nc1)c1N=C1N2CCN(CCCO)CC2)C1=O FHFJVFOTDIRAOD-UHFFFAOYSA-N 0.000 description 1
- JWZQBERYCMZHJF-SFHVURJKSA-N CCCOCCN(c(cc(-c(cn1)ccc1OC)nc1)c1N=C1N2CCN(C[C@H](C)O)CC2)C1=O Chemical compound CCCOCCN(c(cc(-c(cn1)ccc1OC)nc1)c1N=C1N2CCN(C[C@H](C)O)CC2)C1=O JWZQBERYCMZHJF-SFHVURJKSA-N 0.000 description 1
- YXARUBQOXPCFHT-UHFFFAOYSA-N CCCOCCN(c(cc(-c1ccc(C(C)=O)[s]1)nc1)c1N=C1N2CCN(CCO)CC2)C1=O Chemical compound CCCOCCN(c(cc(-c1ccc(C(C)=O)[s]1)nc1)c1N=C1N2CCN(CCO)CC2)C1=O YXARUBQOXPCFHT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- YFDRYBUJCGOYCQ-WDSKDSINSA-N CN1[C@@H](C2)CN[C@@H]2C1 Chemical compound CN1[C@@H](C2)CN[C@@H]2C1 YFDRYBUJCGOYCQ-WDSKDSINSA-N 0.000 description 1
- YFDRYBUJCGOYCQ-PHDIDXHHSA-N CN1[C@H](C2)CN[C@H]2C1 Chemical compound CN1[C@H](C2)CN[C@H]2C1 YFDRYBUJCGOYCQ-PHDIDXHHSA-N 0.000 description 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N Cc1c[nH]nc1 Chemical compound Cc1c[nH]nc1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 1
- VHWFNFITHSPBSR-UHFFFAOYSA-N Cc1c[o]nc1 Chemical compound Cc1c[o]nc1 VHWFNFITHSPBSR-UHFFFAOYSA-N 0.000 description 1
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N Cc1ccncc1 Chemical compound Cc1ccncc1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 1
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79397106P | 2006-04-21 | 2006-04-21 | |
| US60/793,971 | 2006-04-21 | ||
| PCT/IB2007/001001 WO2007122466A1 (en) | 2006-04-21 | 2007-04-10 | Pyridine[3,4-b]pyrazinones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080110930A KR20080110930A (ko) | 2008-12-19 |
| KR101061328B1 true KR101061328B1 (ko) | 2011-08-31 |
Family
ID=38431249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087028465A Expired - Fee Related KR101061328B1 (ko) | 2006-04-21 | 2007-04-10 | 피리딘[3,4-ｂ]피라지논 |
Country Status (41)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007242555B2 (en) | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| HUE025355T2 (en) | 2006-12-12 | 2016-02-29 | Gilead Sciences Inc | Composition for treating pulmonary hypertension |
| PT2247292T (pt) | 2008-03-05 | 2017-07-17 | Merck Patent Gmbh | Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes |
| WO2010041711A1 (ja) * | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| SG10201500511TA (en) * | 2009-10-26 | 2015-03-30 | Signal Pharm Llc | Methods Of Synthesis And Purification Of Heteroaryl Compounds |
| MX346730B (es) | 2010-10-15 | 2017-03-30 | Gilead Sciences Inc | Composiciones y metodos para el tratamiento de la hipertension pulmonar. |
| CA2830027C (en) | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| EP2897964A1 (en) | 2012-09-20 | 2015-07-29 | Pfizer Inc. | Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2956458B1 (en) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
| JP6425717B2 (ja) | 2013-10-04 | 2018-11-21 | ファイザー・インク | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| AP2016009465A0 (en) | 2014-04-01 | 2016-09-30 | Pfizer | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
| CN106459088A (zh) | 2014-04-10 | 2017-02-22 | 辉瑞公司 | 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺 |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| MD20170011A2 (ro) | 2014-08-06 | 2017-08-31 | Pfizer Inc. | Compuşi imidazopiridazinici |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| CN107787322B (zh) | 2015-06-17 | 2023-07-07 | 辉瑞大药厂 | 三环化合物以及它们作为磷酸二酯酶抑制剂的用途 |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| WO2017051303A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド |
| CN113332292A (zh) | 2016-02-23 | 2021-09-03 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
| PT3478679T (pt) | 2016-07-01 | 2021-06-30 | Pfizer | Derivados de 5,7-dihidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas |
| IL271290B2 (en) | 2017-06-22 | 2023-11-01 | Pfizer | Dihydro-pyrrolo-pyridine derivatives |
| US11382918B2 (en) * | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| PT3768669T (pt) | 2018-03-23 | 2023-04-24 | Pfizer | Derivados de piperazina azaspiro |
| US12144815B2 (en) | 2021-02-23 | 2024-11-19 | Hoth Therapeutics, Inc. | Use of aprepitant for treating Alzheimer's disease |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| WO2025145091A1 (en) | 2023-12-29 | 2025-07-03 | Pfizer Inc. | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases |
| WO2025160132A1 (en) * | 2024-01-23 | 2025-07-31 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147199A1 (en) | 2000-03-14 | 2002-10-10 | Degenhard Marx | Process for the treatment of erectile dysfunction and product therefor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1361652A (fr) | 1963-06-21 | 1964-05-22 | Ciba Geigy | Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine |
| HU221425B (en) | 1990-11-06 | 2002-10-28 | Yamanouchi Pharma Co Ltd | Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds |
| TW274550B (https=) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| JP2000154139A (ja) | 1998-09-16 | 2000-06-06 | Kyowa Hakko Kogyo Co Ltd | 縮環ピラジン誘導体 |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| JP4166991B2 (ja) * | 2001-02-26 | 2008-10-15 | 田辺三菱製薬株式会社 | ピリドピリミジンまたはナフチリジン誘導体 |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| US7067658B2 (en) | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
| JP2007504283A (ja) | 2003-05-20 | 2007-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | β−アミロイド斑に作用物質を結合させる方法 |
| EP1641423B1 (en) | 2003-06-26 | 2010-03-17 | Merck Sharp & Dohme Corp. | Benzodiazepine cgrp receptor antagonists |
| DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| EP1833803A4 (en) | 2005-01-03 | 2009-08-05 | Myriad Genetics Inc | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE |
| CA2608672A1 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| JP2009509923A (ja) | 2005-08-26 | 2009-03-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| AU2007242555B2 (en) | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
-
2007
- 2007-04-10 AU AU2007242555A patent/AU2007242555B2/en not_active Ceased
- 2007-04-10 CN CN2007800198932A patent/CN101454320B/zh not_active Expired - Fee Related
- 2007-04-10 ES ES07734320T patent/ES2366239T3/es active Active
- 2007-04-10 EP EP07734320A patent/EP2013208B1/en active Active
- 2007-04-10 MX MX2008012456A patent/MX2008012456A/es active IP Right Grant
- 2007-04-10 DK DK07734320.0T patent/DK2013208T3/da active
- 2007-04-10 PL PL07734320T patent/PL2013208T3/pl unknown
- 2007-04-10 SI SI200730675T patent/SI2013208T1/sl unknown
- 2007-04-10 RS RS20110363A patent/RS51885B/sr unknown
- 2007-04-10 ME MEP-238/08A patent/MEP23808A/xx unknown
- 2007-04-10 JP JP2009505983A patent/JP4436892B2/ja not_active Expired - Fee Related
- 2007-04-10 AT AT07734320T patent/ATE513831T1/de active
- 2007-04-10 KR KR1020087028465A patent/KR101061328B1/ko not_active Expired - Fee Related
- 2007-04-10 WO PCT/IB2007/001001 patent/WO2007122466A1/en not_active Ceased
- 2007-04-10 HR HR20110539T patent/HRP20110539T1/hr unknown
- 2007-04-10 EA EA200801998A patent/EA014919B1/ru not_active IP Right Cessation
- 2007-04-10 BR BRPI0710658-0A patent/BRPI0710658A2/pt not_active IP Right Cessation
- 2007-04-10 RS RSP-2008/0484A patent/RS20080484A/sr unknown
- 2007-04-10 MY MYPI20084131A patent/MY148583A/en unknown
- 2007-04-10 CA CA2649775A patent/CA2649775C/en not_active Expired - Fee Related
- 2007-04-10 AP AP2008004640A patent/AP2408A/xx active
- 2007-04-10 NZ NZ571540A patent/NZ571540A/en not_active IP Right Cessation
- 2007-04-11 NL NL2000583A patent/NL2000583C2/nl not_active IP Right Cessation
- 2007-04-18 AR ARP070101657A patent/AR060525A1/es not_active Application Discontinuation
- 2007-04-18 UY UY30291A patent/UY30291A1/es not_active Application Discontinuation
- 2007-04-19 PE PE2007000483A patent/PE20080192A1/es not_active Application Discontinuation
- 2007-04-19 GT GT200700035A patent/GT200700035A/es unknown
- 2007-04-20 US US11/737,966 patent/US7902195B2/en not_active Expired - Fee Related
- 2007-04-20 PA PA20078724201A patent/PA8724201A1/es unknown
- 2007-04-20 DO DO2007000080A patent/DOP2007000080A/es unknown
- 2007-04-20 TW TW096114037A patent/TWI337609B/zh not_active IP Right Cessation
- 2007-10-04 UA UAA200812397A patent/UA92637C2/ru unknown
-
2008
- 2008-09-29 ZA ZA200808283A patent/ZA200808283B/xx unknown
- 2008-09-29 NO NO20084129A patent/NO20084129L/no not_active Application Discontinuation
- 2008-09-30 CR CR10327A patent/CR10327A/es unknown
- 2008-10-07 IL IL194591A patent/IL194591A/en not_active IP Right Cessation
- 2008-10-08 EC EC2008008803A patent/ECSP088803A/es unknown
- 2008-10-17 TN TNP2008000408A patent/TNSN08408A1/fr unknown
- 2008-10-17 CU CU20080194A patent/CU23777B7/es active IP Right Grant
- 2008-10-21 SV SV2008003074A patent/SV2008003074A/es unknown
- 2008-10-21 MA MA31321A patent/MA30352B1/fr unknown
-
2011
- 2011-07-25 CY CY20111100731T patent/CY1111739T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147199A1 (en) | 2000-03-14 | 2002-10-10 | Degenhard Marx | Process for the treatment of erectile dysfunction and product therefor |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101061328B1 (ko) | 피리딘[3,4-ｂ]피라지논 | |
| JP6689805B2 (ja) | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 | |
| WO2006126081A2 (en) | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors | |
| JP6027989B2 (ja) | Ｍｐｓ１阻害剤としてのピロロピリジンアミノ誘導体 | |
| WO2006126082A2 (en) | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors | |
| JP6297570B2 (ja) | 薬理活性化合物 | |
| EP3405192B1 (en) | Bruton's tyrosine kinase inhibitors | |
| WO2006126083A1 (en) | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors | |
| WO2017066014A1 (en) | Bruton's tyrosine kinase inhibitors | |
| EA029757B1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN106459035B (zh) | N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途 | |
| TW202122382A (zh) | 乙內醯脲衍生物 | |
| RS20050832A (sr) | Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti | |
| WO2007020521A1 (en) | Pyridoyrazinones as pde-5 inhibitors | |
| JP2008510734A (ja) | キナーゼ阻害剤 | |
| HK1133875B (en) | Pyridine[3,4-b]pyrazinones | |
| CN121816347A (zh) | 药物化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20140730 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170826 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170826 |